News | June 18, 2007

HF Biomarker Reduces ED Visits by 21 Percent

June 19, 2007 - A study published today in Circulation shows that the use of NT-proBNP (N-terminal proB-type natriuretic peptide), a biomarker by Roche Diagnostics for suspected heart failure (HF), reduced emergency department (ED) visits by 21 percent.

The multi-center trial, which included 500 patients and seven hospitals, also showed that NT-proBNP guided strategy in the management of suspected acute HF in the ED lowered the number of patients re-hospitalized over 60 days by 35 percent, and trimmed direct medical costs of all ED visits, hospitalizations and subsequent outpatient services by 15 percent over 60 days from enrollment.

NT-proBNP and B-type natriuretic peptide (BNP) have been shown to provide incremental value in the rapid diagnosis of HF in the emergency room. Due to its greater stability, NT-proBNP may represent a more useful diagnostic marker than BNP for cardiovascular disorders including HF.

“An approach using NT-proBNP in conjunction with clinical assessment improves the overall management of patients presenting to the emergency department with suspected acute HF through the facilitation of diagnosis, and provides health cost savings that are accompanied by an improvement in selected clinical outcomes,” said Gordon W. Moe, M.D., a cardiologist and director of the heart failure program and biomarker laboratory at St. Michael’s Hospital in Toronto, Canada, who chaired the study.

For more information: www.roche.com

Related Content

Siemens Healthineers to Acquire Epocal from Alere
News | Point of Care Testing| July 26, 2017
Siemens Healthineers has entered into a definitive agreement to acquire Epocal Inc., a subsidiary of Alere Inc. Epocal...
Alere point of care POC testing for INR
News | Point of Care Testing| July 17, 2017 | Dave Fornell
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is on
Sponsored Content | Videos | Cardiovascular Ultrasound| June 07, 2017
Chi-Ming Chow, M.D., MSc, FRCPC, FACC, FASE, attending staff cardiologist, St.
Siemens Xprecia Stride anticoagulation, coagulation PT/INR or INR testing at the point of care (POC)

Point-of-care coagulation PT/INR testing with handheld devices can help improve outcomes with more convenient and frequent measurements to keep patients within the therapeutic range of anticoagulant agents.

Feature | Point of Care Testing| May 05, 2017 | Nicholas C. Vanderslice, Ph.D., and Arnol S. Rios
Point-of-care (POC) coagulation analyzers that measure prothrombin time/international normalized ratio (PT/INR) on fi
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing| April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
HyperMed Imaging, HyperView portable tissue oxygenation measurement system, FDA clearance
Technology | Point of Care Testing| January 27, 2017
HyperMed Imaging Inc. announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the...
Suntech Medical, Oscar 2 ambulatory blood pressure monitoring system, ABPM, Patient Diary App, SphygmoCor Inside
Technology | Blood Pressure Monitor| January 17, 2017
The new SunTech Oscar 2 24-hour ambulatory blood pressure monitoring system is now available with the True24 ABPM...
GE Healthcare, Vscan Extend, app-based ultrasound, dual-probe, RSNA 2017
Technology | Ultrasound Imaging| January 12, 2017
GE Healthcare unveiled its new generation of pocket-sized, dual-probe ultrasound, the Vscan Extend. From the hospital...
News | Atrial Fibrillation| January 04, 2017
January 4, 2017 — A smartphone application made it possible to use the iPhone camera to detect atrial fibrillation vi

The Xprecia Stride Coagulation Analyzer delivers fast, reliable prothrombin time/international normalized ratio (PT/INR) testing for point-of-care monitoring and management of oral anticoagulation therapy with warfarin, a vitamin K antagonist. It is the latest INR testing system to enter the market in late 2016. Read the article “Siemens Receives FDA Clearance of Xprecia Stride Coagulation Analyzer.”
 

 

Feature | Point of Care Testing| December 30, 2016 | Ravi Chawat
Point of care testing devices are gaining widespread approval for prompt medical diagnoses, especially in cardiology
Overlay Init